Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Autoimmune disease

Psoriasis

S100 calcium binding protein A9 (S100A9; calgranulin B; MRP14); complement 3 (C3)

Studies in human samples and mice suggest inhibiting S100A9 or C3 could help treat psoriasis. In skin samples from patients with psoriasis and in mouse models of psoriasis, levels of S100A9 and C3 in psoriatic lesions were higher than those in normal patients or mouse skin. In the mouse models, S100a9 deficiency decreased plaque sizes, numbers of infiltrating immune cells and levels of C3 and proinflammatory cytokines compared with normal S100a9 expression. In the mouse models, C3 siRNA decreased plaque size on the ears compared with scrambled siRNA. Ongoing work includes testing Active Biotech AB's tasquinimod, an S100A9-binding compound, in mouse models of psoriasis.
Tasquinimod (ABR215050) is partnered with Ipsen Group and is in Phase III testing to treat metastatic castration-resistant prostate cancer (CRPC) and Phase II testing to treat other solid tumors.
Potentia Pharmaceuticals Inc. and Novartis AG have compstatin (APL-1), a C3 inhibitor, in Phase II testing to treat age-related macular degeneration (AMD).

SciBX 7(2); doi:10.1038/scibx.2014.44
Published online Jan. 16, 2014

Unpatented; unlicensed

Schonthaler, H.B. et al. Immunity; published online Dec. 12, 2013;
doi:10.1016/j.immuni.2013.11.011
Contact: Erwin F. Wagner, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
e-mail:
ewagner@cnio.es